A recent study showed that OBD9, an oxetane derivative of the benzimidazole mebendazole with TNIK inhibitory activity, exhibits strong anticancer activity in various cancer cells, particularly colorectal cancer, by inducing TNIK autophagic degradation and blocking TCF4/β-catenin-mediated gene expression [143]. Here, TNIK is linked to cancer.